Craig C. Reed
Research Subjects
Craig C. Reed has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Evan S. Dellon
Center for Esophageal Diseases and Swallowing, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA
7 shared publications - Swathi Eluri
Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, NC
6 shared publications - Nicholas J. Shaheen
Division of Gastroenterology and Hepatology, Center for Esophageal Diseases and Swallowing, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
5 shared publications Evan S. Dellon
4 shared publicationsBenjamin Robey
3 shared publicationsClaire Fan
3 shared publications
Latest Publications
- 30 September 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 527
Authors’ response
- 30 September 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 527
Authors’ response
- 6 June 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 492-497
Nasal and inhaled steroid use does not influence treatment response outcomes in eosinophilic esophagitis
- 6 June 2026
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 137 (4) , 492-497
Nasal and inhaled steroid use does not influence treatment response outcomes in eosinophilic esophagitis
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 9 December 2025
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 121 (9) , 2149-2157
An Eosinophilic Esophagitis Endoscopic Reference Score Threshold of 2 or Less Is Robust for Assessing Endoscopic Response to Treatment of Eosinophilic Esophagitis
INTRODUCTION: Assessment of eosinophilic esophagitis (EoE) endoscopic findings is critical in determining disease activity. However, response thresholds for the EoE Endoscopy Reference Score (EREFS) are not definitively established. We assessed EREFS response thresholds in patients with EoE treated with topical corticosteroids. METHODS: We conducted a retrospective cohort study of newly diagnosed patients with EoE treated with topical corticosteroid who had a follow-up endoscopy with biopsy and EREFS assessed pretreatment/post-treatment. We explored endoscopic response thresholds. Patients with and without endoscopic response were compared and predictors of response were determined. Histologic and global symptom responses were determined and residual endoscopic findings calculated. RESULTS: Of 333 patients, 219 (68%), 206 (62%), 142 (43%), 70 (21%), 139 (42%), and 142 (43%) met response thresholds for EREFS ≤2, EREFS ≤2 with no components >1 nor worsening of any component, EREFS ≤1, EREFS = 0, inflammatory subscore = 0, and fibrostenotic subscore = 0, respectively. On multivariate analysis, lower body mass index (adjusted odds ratio [aOR]: 0.90; 95% confidence interval [CI]: 0.85–0.95), heartburn (aOR: 2.74; 95% CI: 1.37–5.48), and lower total baseline EREFS (aOR: 0.57; 95% CI: 0.29–0.71) independently predicted EREFS ≤2. After treatment, 74% with EREFS≤2 vs 23% with EREFS>2 ( P < 0.001) had histologic response at P < 0.001) and had minimal residual endoscopic findings. Outcomes stratified for adults and children were comparable with the entire cohort. DISCUSSION: Post-treatment EREFS ≤2 was consistent with symptom and histologic response for the entire cohort. These data support EREFS ≤2 as a robust threshold to define endoscopic response.
- 16 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1813-1820
The Natural History of Eosinophilic Gastrointestinal Diseases Is Influenced by Age of Onset and Location of Involvement
INTRODUCTION: It is unknown whether concomitant esophageal involvement or anatomic location of eosinophilic infiltration affects the natural history of eosinophilic gastrointestinal disease (EGID). METHODS: A retrospective cohort study was performed using the University of North Carolina EGID Clinicopathologic Database. Patients were adults and children with a prior EGID diagnosis based on clinicopathologic features. Demographics, clinical characteristics, treatment information, and procedural data were extracted from medical records. Clinical course and flare history were characterized. RESULTS: Among 97 patients, 43% had EGID + esophageal involvement and 57% had EGID only. Patients with esophageal involvement had a longer diagnostic delay preceding diagnosis (36.6 vs 11.6 months, P = 0.001), more dysphagia (50% vs 18%; P = 0.001), required more chronic therapy (77% vs 52%, P = 0.016), and exhibited more progressive disease (25% vs 6%, P = 0.027). A continuous disease course was most common in eosinophilic gastritis (78%) while patients with eosinophilic gastritis + eosinophilic enteritis (29%) and eosinophilic enteritis + eosinophilic colitis (50%) had the highest proportion of progressive and relapsing disease, respectively (P = 0.045). A continuous disease course occurred more frequently in children (71%, P = 0.03) and those with single organ involvement (65%), whereas adults had more relapsing (39%) or progressive disease (18%). DISCUSSION: EGIDs with and without esophageal involvement display many similarities, although patients with esophageal involvement more frequently had dysphagia, had progressive disease courses, and required more chronic therapy. Location of involvement and age of onset affected the natural history with higher proportions of relapsing or progressive disease seen in adults and patients with small bowel or multiorgan involvement while a continuous disease course was more common in children and patients with gastric-only involvement.
- 16 May 2024
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 119 (9) , 1813-1820
The Natural History of Eosinophilic Gastrointestinal Diseases Is Influenced by Age of Onset and Location of Involvement
INTRODUCTION: It is unknown whether concomitant esophageal involvement or anatomic location of eosinophilic infiltration affects the natural history of eosinophilic gastrointestinal disease (EGID). METHODS: A retrospective cohort study was performed using the University of North Carolina EGID Clinicopathologic Database. Patients were adults and children with a prior EGID diagnosis based on clinicopathologic features. Demographics, clinical characteristics, treatment information, and procedural data were extracted from medical records. Clinical course and flare history were characterized. RESULTS: Among 97 patients, 43% had EGID + esophageal involvement and 57% had EGID only. Patients with esophageal involvement had a longer diagnostic delay preceding diagnosis (36.6 vs 11.6 months, P = 0.001), more dysphagia (50% vs 18%; P = 0.001), required more chronic therapy (77% vs 52%, P = 0.016), and exhibited more progressive disease (25% vs 6%, P = 0.027). A continuous disease course was most common in eosinophilic gastritis (78%) while patients with eosinophilic gastritis + eosinophilic enteritis (29%) and eosinophilic enteritis + eosinophilic colitis (50%) had the highest proportion of progressive and relapsing disease, respectively (P = 0.045). A continuous disease course occurred more frequently in children (71%, P = 0.03) and those with single organ involvement (65%), whereas adults had more relapsing (39%) or progressive disease (18%). DISCUSSION: EGIDs with and without esophageal involvement display many similarities, although patients with esophageal involvement more frequently had dysphagia, had progressive disease courses, and required more chronic therapy. Location of involvement and age of onset affected the natural history with higher proportions of relapsing or progressive disease seen in adults and patients with small bowel or multiorgan involvement while a continuous disease course was more common in children and patients with gastric-only involvement.
- 10 January 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 411-412
Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
- 10 January 2024
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (3) , 411-412
Editorial: Eosinophilic oesophagitis coming of age—Increasing frequency and wider age range—Authors' reply
- 25 October 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (2) , 260-268
Retrospective cohort study: Effect of age as a barrier to diagnosis of eosinophilic oesophagitis
Summary: Background: Prior work suggests eosinophilic oesophagitis (EoE) is rare in those aged over 65 years. However, elderly patients with EoE experience a substantial diagnostic delay from symptom onset to diagnosis.Aims: To assess if age predicted whether oesophageal biopsies were obtained in patients with EoE symptoms, what clinical features predict EoE in the elderly, and if EoE phenotype differs between elderly and non‐elderly patients.Methods: We conducted a retrospective cohort study utilising the University of North Carolina (UNC) electronic medical record, EoE clinicopathologic database and UNC endoscopy software from July 2008 to April 2021. A sample of 193 elderly and non‐elderly patients with dysphagia, chest pain and/or heartburn were assembled. Patients with EoE were newly diagnosed per contemporaneous guidelines. Patient demographics, clinical characteristics and procedural data were extracted. Summary statistics, bivariate and multivariate analyses were performed.Results: Of 193 patients, we included 91 elderly (47%) and 102 non‐elderly (53%). Age independently predicted the odds of biopsies (adjusted odds ratio (aOR): 0.44 elderly vs. non‐elderly; 95% CI: 0.21–0.92). Endoscopic features of EoE, but not symptoms, were more common in elderly than non‐EoE elderly patients. Elderly patients with EoE differed from non‐elderly only by time to diagnosis (aOR per year of symptoms preceding diagnosis: 1.08, 95% CI: 1.04–1.11).Conclusions: Elderly patients with EoE have <50% the odds of oesophageal biopsies. There were no significant differences between elderly and non‐elderly EoE patients, although endoscopic features helped discriminate the two groups. Our findings suggest that older age represents a barrier to EoE diagnosis.
- 25 October 2023
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 59 (2) , 260-268
Retrospective cohort study: Effect of age as a barrier to diagnosis of eosinophilic oesophagitis
Summary: Background: Prior work suggests eosinophilic oesophagitis (EoE) is rare in those aged over 65 years. However, elderly patients with EoE experience a substantial diagnostic delay from symptom onset to diagnosis.Aims: To assess if age predicted whether oesophageal biopsies were obtained in patients with EoE symptoms, what clinical features predict EoE in the elderly, and if EoE phenotype differs between elderly and non‐elderly patients.Methods: We conducted a retrospective cohort study utilising the University of North Carolina (UNC) electronic medical record, EoE clinicopathologic database and UNC endoscopy software from July 2008 to April 2021. A sample of 193 elderly and non‐elderly patients with dysphagia, chest pain and/or heartburn were assembled. Patients with EoE were newly diagnosed per contemporaneous guidelines. Patient demographics, clinical characteristics and procedural data were extracted. Summary statistics, bivariate and multivariate analyses were performed.Results: Of 193 patients, we included 91 elderly (47%) and 102 non‐elderly (53%). Age independently predicted the odds of biopsies (adjusted odds ratio (aOR): 0.44 elderly vs. non‐elderly; 95% CI: 0.21–0.92). Endoscopic features of EoE, but not symptoms, were more common in elderly than non‐EoE elderly patients. Elderly patients with EoE differed from non‐elderly only by time to diagnosis (aOR per year of symptoms preceding diagnosis: 1.08, 95% CI: 1.04–1.11).Conclusions: Elderly patients with EoE have <50% the odds of oesophageal biopsies. There were no significant differences between elderly and non‐elderly EoE patients, although endoscopic features helped discriminate the two groups. Our findings suggest that older age represents a barrier to EoE diagnosis.
- 1 September 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 92 (3) , 779
Aortoenteric fistula complicating lumen-apposing metal stent placement for a benign anastomotic stricture
- 1 September 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 92 (3) , 779
Aortoenteric fistula complicating lumen-apposing metal stent placement for a benign anastomotic stricture
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-251-251
Sa1130 - The Distal Esophagus is the Most Commonly Involved Site for Strictures in Patients with Eosinophilic Esophagitis
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6) , S-251-251
Sa1130 - The Distal Esophagus is the Most Commonly Involved Site for Strictures in Patients with Eosinophilic Esophagitis
- 18 April 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (8) , 2136-2145
Natural History of the Post-ablation Esophagus
Endoscopic ablative therapy including radiofrequency ablation (RFA) represents the preferred management strategy for dysplastic Barrett’s esophagus (BE) and appears to diminish the risk of developing esophageal adenocarcinoma (EAC). Limited data describe the natural history of the post-ablation esophagus. Recent findings demonstrate that recurrent intestinal metaplasia (IM) following RFA is relatively frequent. However, dysplastic BE and EAC subsequent to the complete eradication of intestinal metaplasia (CEIM) are uncommon. Moreover, data suggest that the risk of recurrent disease is probably highest in the first year following CEIM. Recurrent IM and dysplasia are usually successfully eradicated with repeat RFA. Future studies may refine surveillance intervals and inform the length of time surveillance should be conducted following RFA with CEIM. Further data will also be necessary to understand the utility of chemopreventive strategies, including NSAIDs, in reducing the risk of recurrent disease.
- 18 April 2018
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 63 (8) , 2136-2145
Natural History of the Post-ablation Esophagus
Endoscopic ablative therapy including radiofrequency ablation (RFA) represents the preferred management strategy for dysplastic Barrett’s esophagus (BE) and appears to diminish the risk of developing esophageal adenocarcinoma (EAC). Limited data describe the natural history of the post-ablation esophagus. Recent findings demonstrate that recurrent intestinal metaplasia (IM) following RFA is relatively frequent. However, dysplastic BE and EAC subsequent to the complete eradication of intestinal metaplasia (CEIM) are uncommon. Moreover, data suggest that the risk of recurrent disease is probably highest in the first year following CEIM. Recurrent IM and dysplasia are usually successfully eradicated with repeat RFA. Future studies may refine surveillance intervals and inform the length of time surveillance should be conducted following RFA with CEIM. Further data will also be necessary to understand the utility of chemopreventive strategies, including NSAIDs, in reducing the risk of recurrent disease.